1 – 10 of 147
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
(
- Contribution to journal › Article
-
Mark
Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification
(
- Contribution to journal › Letter
- 2022
-
Mark
Regional differences in treatment and outcome for myeloma patients in Sweden : A population based Swedish myeloma register study
(
- Contribution to journal › Article
-
Mark
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia : Results from the HEAT-AML trial
(
- Contribution to journal › Article
-
Mark
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
(
- Contribution to journal › Article
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
2022) In Blood Advances(
- Contribution to journal › Article
- 2021
-
Mark
Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
(
- Contribution to journal › Article
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
(
- Contribution to journal › Article
-
Mark
Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years
(
- Contribution to journal › Article